These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8493426)

  • 1. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analyses, stopping rules and data monitoring in clinical trials in Europe.
    Buyse M
    Stat Med; 1993 Mar; 12(5-6):509-20. PubMed ID: 8493429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ
    J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model for the interim analysis process: a case study.
    Delgado-Herrera L; Anbar D
    Control Clin Trials; 2003 Feb; 24(1):51-65. PubMed ID: 12559642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of clinical trials: issues and recommendations.
    Fleming TR; DeMets DL
    Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccine THERATOPE- Biomira.
    Adis International Ltd
    Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the unblinded sponsor statistician.
    Snapinn S; Cook T; Shapiro D; Snavely D
    Stat Med; 2004 May; 23(10):1531-3. PubMed ID: 15122733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases.
    Ellenberg SS; Myers MW; Blackwelder WC; Hoth DF
    Stat Med; 1993 Mar; 12(5-6):461-7; discussion 469. PubMed ID: 8493424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring factors associated with views on sharing of certain interim trial result measures by the data safety monitoring board (DSMB) with non-DSMB members.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 Nov; 19(1):621. PubMed ID: 30419939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of interim analyses in drug development.
    Facey KM; Lewis JA
    Stat Med; 1998 Aug 15-30; 17(15-16):1801-9; discussion 1811-2. PubMed ID: 9749448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry.
    Enas GG; Dornseif BE; Sampson CB; Rockhold FW; Wuu J
    Control Clin Trials; 1989 Mar; 10(1):57-70. PubMed ID: 2702837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.